Download PDF
1
/
Pages
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
F. Barata; H. Queiroga; E. Teixeira; T. Almodovar; M. Soares; B. Parente; J.C. Mellidez; P. Alves; A. Antunes;
Pulmonol. 2021;27:175-7
Unresectable stage III non-small cell lung cancer: Insights from a Portuguese expert panel
A. Araújo; A. Barroso; B. Parente; C. Travancinha; E. Teixeira; F. Martelo; G. Fernandes; G. Paupério; H. Queiroga; I. Duarte; J.D. da Costa; M. Soares; P. Borralho; P. Costa; P. Chinita; T. Almodôvar; F. Barata;
Pulmonol. 2024;30:159-69
KIF5B-MET fusion variant in non-small cell lung cancer
M. Costa e Silva; I. Sucena; L. Cirnes; J.C. Machado; S. Campainha; A. Barroso;
Pulmonol. 2022;28:315-6